Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03717025
Other study ID # INT/IEC/2017/1251
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2017
Est. completion date November 2018

Study information

Verified date October 2018
Source Postgraduate Institute of Medical Education and Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Comparing the Efficacy of Three Different Surgical Methods on Resistant Sites in Stable Vitiligo.


Description:

The treatment of vitiligo includes both medical and surgical modalities, whose goal is to restore melanocytes to the depigmented skin so that the epidermis restores back to normal morphology and functions. Although medical treatment is the main stay of treatment, it is not effective in all and residual lesions need augmented surgical treatment later for further completion of repigmentation.

Now a day surgical modalities have become treatment of choice for stable vitiligo not responding to medical treatment although there are numerous sites which do not respond that well to surgical procedure as well. The investigators ought to compare the efficacy of 3 well established surgical methods i.e. Mini Punch Grafting vs Suction Blister Epidermal Grafting vs Non Cultured Epidermal cell Suspension on stable vitiligo patches localized to acral areas and bony prominences like elbows, knees and ankles. Out of all the vitiligo patches in a given participant, 3 different patches on acral and bony areas will be chosen and participants will be treated with 3 different methods.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date November 2018
Est. primary completion date October 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subjects with clinical diagnosis of focal, segmental or generalized vitiligo

2. Patients with lesions of size > 1.5cm x 1cm present on acral areas and bony prominences.

3. Vitiligo lesions has been stable for 1 year.

4. Disease not responding to medical treatment, or there are residual patches (after medical therapy) of vitiligo which inturn are located on acral areas and bony prominences.

5. Maximum size of vitiligo patches to be selected for surgery will not be >100cm2.

Exclusion Criteria:

1. Age less than 18 years

2. Pregnancy and lactation

3. Patient with actively spreading vitiligo

4. History of Koebnerisation

5. History of hypertrophic scars or keloidal tendency

6. Bleeding disorders

7. Patients with unrealistic expectation

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
SUCTION BLISTER EPIDERMAL GRAFTING
Preferred donor sites for making blister is lateral aspect of upper thigh. The area is shaved and cleansed with surgical spirit. Blister formation is induced by using suction apparatus. Recipient site is surgically prepared by doing dermabrasion. After formation of blisters, each blister is gently cleansed with normal saline and cut all along its border with curved iris scissors parallel to the skin surface. The roof is everted over the thumb with dermal surface facing upwards and then with the help of blunt end of forceps it is placed on the recipient area. The graft is firmly pressed with sterile moist gauze to remove any underneath serous collection. The pressure dressing is done with double layer framycetin tulle, moist gauze and bandage. Donor area is dressed with dry sterile pads. The part is immobilized and Antibiotics and Analgesic are given till dressing are removed (after 5-7 days).
MINI PUNCH GRAFTING
Recipient area is prepared first after shaving and cleaning with surgical spirit. 2 % lignocaine with or without adrenalin will be infiltrated as local aneasthetic. The punched out chambers are spaced at a gap of less than 5 mm (preferably 2 - 2.5 mm) from each other. The donor area is either upper lateral portion of thigh or gluteal region. Grafts are placed directly from donor to the recipient area. Care is taken, so that graft edges are not folded, the tissue is not crushed or placed upside down. Hemostasis is achieved by pressing a saline soaked gauze piece over the area. For the recipient area 3 layers of dressing from inside out are : paraffin embedded non adherent sterile gauze, sterile surgipad, and micropore. For the donor area only surgipad and micropore are used. Immobilisation of recipient area is advised along with antibiotics and analgesics till removal of dressing (after 4-7 days).
NON CULTURED EPIDERMAL CELL SUSPENSION
About one-tenth the size of recipient area is selected as the donor site. Split thickness skin graft is taken under aseptic precautions with the help of a shaving blade held firmly by a straight artery forceps. The area is dressed with Bactigras gauze. Split thickness skin specimen is transferred under aseptic conditions to a container with Normal Saline and transferred to laboratory for preparing suspension. Recipient site is dermabraded under aseptic precautions until tiny pinpoint bleeding spots are seen. Epidermal cell suspension is carefully transferred to a tuberculin syringe. With 18 gauge needle attached to this syringe, suspension is spread evenly on dermabraded recipient site. This is then covered with Collagen dressing, followed by bactigras, guaze and tegaderm dressings from inside to outside. The patient is observed for 2 hours after performing the procedure and given antibiotics and analgesics for 5-7 days till dressing removal.

Locations

Country Name City State
India Post Graduate Institute of Medical Education and Research Chandigarh

Sponsors (1)

Lead Sponsor Collaborator
Postgraduate Institute of Medical Education and Research

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Repigmentation At Surgery Site To assess the difference in extent of repigmentation of the surgery site by three different methods at 12 weeks of post treatment follow up in a given patient.
Repigmentation will be assessed as follows:
=25% Minimal repigmentation 26-50% Mild repigmentation 51-75% Moderate repigmentation 76-90% Marked repigmentation >90% Excellent repigmentation
Repigmentation will be assessed at 12 weeks.
Secondary Color Matching of Repigmented Area Color matching of the repigmented area with the surrounding normal skin will be done in each case as 'somewhat lighter than', 'same as' or 'somewhat darker than' normal skin. Assessment at 12 weeks.
Secondary Patient's Quality of Life Post Surgery Patient satisfaction will be assessed using Patient Global Assessment score. Assessment at 12 weeks.
Secondary Patient's Quality of Life Post Surgery Quality of life assessement post procedure will be done using Vitiligo specific questionnaire. Assessment at 12 weeks.
Secondary PATTERN OF REPIGMENTATION Pattern of repigmentation attained post-procedure will be noted as 'diffuse', 'perifollicular' or 'migrating from the borders'. Assessment at 12 weeks.
Secondary ADVERSE EVENTS Adverse events both at recipient and donor sites. Assessment at 4, 8 and 12 weeks.
See also
  Status Clinical Trial Phase
Completed NCT05298033 - Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo Phase 2
Recruiting NCT05872477 - Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas Phase 2
Terminated NCT04374435 - Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo N/A
Completed NCT04103060 - Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo Phase 2
Terminated NCT04271501 - Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions N/A
Completed NCT04530344 - Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo Phase 3
Not yet recruiting NCT05008887 - Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo Phase 4
Terminated NCT02191748 - Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo Phase 2/Phase 3
Completed NCT01382589 - Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Phase 2
Terminated NCT01262547 - A New Micrografting Technique for Vitiligo Phase 2
Active, not recruiting NCT04971200 - Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo Early Phase 1
Completed NCT04872257 - Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo N/A
Completed NCT04547998 - Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions N/A
Not yet recruiting NCT04039451 - Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
Not yet recruiting NCT03611348 - Microneedling and Latanoprost in Acrofacial Vitiligo Phase 2/Phase 3
Recruiting NCT03199664 - Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo Phase 4
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Completed NCT03249064 - Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo N/A
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT04246372 - Tofacitinib for Immune Skin Conditions in Down Syndrome Phase 2